Skip to main content
Premium Trial:

Request an Annual Quote

MGI Tech, Swift Biosciences to Jointly Market Library Prep Products in Europe and Asia Pacific

NEW YORK – Swift Biosciences and MGI Tech, a subsidiary of the BGI Group, said on Tuesday that they have signed an agreement to jointly market Swift's library preparation products in Europe and Asia Pacific.

Under the partnership, the companies will make Swift's library prep kits compatible with MGI's DNBSEQ sequencers, starting with the 2S Turbo DNA kit for whole-genome and targeted sequencing and the Rapid RNA and Methyl-Seq DNA Library kits.

"MGI is a valued partner and we will continue to grow the relationship," said Swift President and CEO Nathan Wood in a statement. "We have several exciting products launching this year and our R&D and manufacturing groups will be looking to enable the technology on the MGI platform as we continue our strategic worldwide growth."

MGI Chief Operating Officer Jiang Hui said in the statement that with this partnership, "MGI is demonstrating its commitment to continue opening its platform and bring more applications to our sequencing and grow our application community in order to support our customers."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.